Summary: Onco-this-Week presents an ASCO-special bulletin, where we have listed down the major oncology companies who are showcasing their clinical updates and portfolios at the upcoming annual meeting at Chicago. Highlighting this year’s theme, “delivering discoveries: expanding the reach of precision medicine”, Dr. Bruce Johnson, President, ASCO, emphasizes the focus on development of precision medicine for it to become a reality for every patient. Stay tuned as we would be bringing you the latest results including data from CheckMate -227, CheckMate -238, PIVOT, ADMYRE trial, Ph III KEYNOTE-407 and -042, and results from trials of Merck KGaA’s TGF ß trap/anti-PD-L1 bi-functional antibody, investigational ADC moxetumomab pasudotox, radium Ra 223 dichloride in mCRPC and much more.
From Visually.
This edition of Onco-this-Week is Sponsored by Nano-Tag Biotechnologies
Note from our Sponsor: “Make our Single-domain Antibody (sdAb) fit your application! We can fuse our Tags to many proteins or biomolecules of your choice. If you need them coupled to biotin, streptavidin, HRP, GFP, Fc domains or any other biomolecule, feel free to contact us.”
“NanoTag Biotechnologies is a German company founded in July 2015 by scientists with a strong background in biochemistry as well as quantitative super-resolution imaging. Situated in Göttingen, we are in constant exchange with scientists developing and applying tools for innovative cutting-edge research. The inspiring atmosphere created by leading scientists and an excellent network of entrepreneurship is an ideal breeding ground for our vision to produce thoroughly validated high-quality tools for life-sciences, biotechnology and bio-medical research. Currently, our portfolio mainly focuses on single-domain antibody-based affinity reagents (“Tags”) for biochemical and fluorescence-based applications. In the near future, we are going to expand our portfolio to enzymes, affinity resins and secondary reagents for various immunoassays (IP, IF, IHC, IHC-P, WB…). Feel free to contact us anytime to discuss custom projects.”
Cover image: [Courtesy: Felipe Opazo (CEO) Nano-Tag Biotechnologies]3T3 cells transfected with the mitochondrial marker Tom70-mTagBFP, stained with FluoTag-Q anti-TagFP Atto542. Shown is the signal of FluoTag-Q anti-TagFP Atto542. (For more info click here)
touchONCOLOGY at @ASCO 2018 will be hosting a 60min live broadcast Wednesday 6 June 2018 at 13:00CEST where world-renowned expert, Prof Nadia Harbeck, will be discussing key data in advanced #BreastCancer
Register today! https://t.co/EuvAvXY283 #Cancer #Oncologists #ASCO #ASCO18 pic.twitter.com/F3YJNPztKW— touchONCOLOGY (@touchONCOLOGY) May 18, 2018
CONFERENCE COVERAGE
ASCO President, Bruce E. Johnson, MD, FASCO, welcomes patient advocates to the 2018 ASCO Annual Meeting.
Clinical updates from key Oncology players to be presented at ASCO 2018 Annual Meeting
- Merck data to showcase progress and further optionality of oncology pipeline
- Nektar Therapeutics announces six abstracts accepted for presentation
- Janssen to present new data in urothelial, hematologic and prostate cancers
- BerGenBio to present interim clinical and biomarker data from Phase II development programme with selective AXL inhibitor bemcentinib
- Array BioPharma announces oral presentation from the pivotal Phase 3 COLUMBUS trial of the combination of Encorafenib and Binimetinib in patients with BRAF-mutant melanoma
- Daiichi Sankyo to present new data on multiple compounds including Antibody Drug Conjugates DS-8201 and U3-1402
- Forty Seven, Inc. to present clinical data on 5F9, its first-in-class CD47 antibody
- Lilly data illustrate patient-driven advances in cancer care
- Regeneron and Sanofi share first positive clinical data for Cemiplimab in advanced non-small cell lung cancer
- Astellas announces abstracts highlighting growing oncology portfolio
- Epic Sciences and its collaborators to present new data
- MEI Pharma to present clinical data
- AbbVie to show progress and growth in oncology research
- bluebird bio to present updated clinical results from ongoing multicenter Phase 1 Study of bb2121 anti- BCMA CAR T cell therapy in patients with late stage relapsed/refractory Multiple Myeloma
- Loxo Oncology announces details of LOXO-292 clinical data presentations
- Jounce Therapeutics to present data from ongoing ICONIC trial of JTX-2011
- Syndax announces updated results from Phase 2 ENCORE 601 trial of Entinostat in combination with KEYTRUDA® (pembrolizumab)
- ImmunoGen announces positive findings from the FORWARD II study of Mirvetuximab Soravtansine combination regimens with Avastin® and Carboplatin in Ovarian Cancer
- Bayer highlights latest oncology research
- Eisai to present data on oncology pipeline and products
- Takeda to highlight broad oncology portfolio and pipeline data
- Pfizer Oncology to showcase clinical advances from its growing portfolio and research pipeline
- Bristol-Myers Squibb highlights breadth of Immuno-oncology–based combination research and commitment to advancing precision medicine
- New data from Merck’s leading Immuno-oncology clinical development program in over 25 tumor types
- Boston Biomedical, Inc. announces presentations for investigational agents Napabucasin and DSP-7888 (ombipepimut-S*)
TRIAL STATUSES
First cohort of patients dosed in ongoing Ph Ib/II trial of PCM-075 in AML
“We are pleased that the combination of PCM-075 and LDAC was well tolerated and that the SRC recommended we advance to our second dose cohort,” said Bill Welch, Chief Executive Officer of Trovagene. “Investigator interest in our development program is high and we are encouraged by the steady activity across our eight activated clinical sites to identify patients.”
Myeloblasts with Auer rod in acute myeloid leukemia pic.twitter.com/uMt9PNRrbw
— Internal medicine (@IMmemorandum) June 28, 2014
“Dendreon led the way with PROVENGE, the first active cellular immunotherapy approved by the FDA,” said Jim Caggiano, chief executive officer of Dendreon. “We have already established that PROVENGE helps mCRPC patients live longer, and physicians have prescribed it to over 30,000 men. With this trial, Dendreon is taking another leadership position in the treatment of prostate cancer; if successful, it could again revolutionize the way the disease is treated.”
“The large body of data collected on PROVENGE has proven it has a significant impact on increasing overall survival in men with mCRPC,” said Bruce A. Brown, M.D., senior vice president, medical, at Dendreon. “With the ProVent trial, our aim is to determine if PROVENGE can reduce prostate cancer disease progression in men on AS and potentially provide an alternative to choosing a treatment that can negatively impact quality of life.”
Video of my presentation showing sipuleucel-T induced T cells killing target cells in human samples. https://t.co/h3oEyQmjVR
— Brant Inman (@BrantInman) May 19, 2018
Infographically Speaking…..
From Visually.
About the Author:
Richa earned her PhD at the National Brain Research Centre, India. For her thesis, she worked on the dreaded Glioblastoma multiforme. That was her first in-depth exposure to academic research in cancer biology. After her PhD, she expanded her research experience by working in the field of immunology at UCLA, USA. After her return to India, Richa switched to a corporate setting but continued her engagement with the cancer field. She is currently loving her work, which affords her the opportunity to continue developing her knowledge in the biomedical field of cancer. Outside of work, she enjoys watching, identifying and photographing birds.
Editor and Blog Design:
Abhi graduated from the Molecular Biophysics Unit of IISc (Bangalore, India) in 2011. As a Biomedical Scientist, he has worked with all three life-forms in his 13-year research career, viz., particulate, unicellular and multicellular. He is currently an Assistant Scientist at Emory University (Atlanta, GA) studying mechanisms of tumor recurrence in kids with brain tumors. As a postdoctoral fellow, he was the recipient of two Young Investigator Awards from Alex Lemonade Stand Foundation (Philadelphia, PA) and Rockland Immunochemicals. His current research has been funded by Northwestern Mutual Foundation (Milwaukee, WI), CURE Childhood Cancer Foundation (Atlanta, GA) and American Association for Cancer Research (AACR). When he is not on the bench you will find him spending time with his family or exploring the world through traveling and blogging.
Image Sources: Wikipedia and Twitter
The contents of Club SciWri are the copyright of PhD Career Support Group for STEM PhDs {A US Non-Profit 501(c)3}. (PhDCSG is an initiative of the alumni of the Indian Institute of Science, Bangalore. The primary aim of this group is to build a NETWORK among scientists, engineers and entrepreneurs).
This work by Club SciWri is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Disclaimer: The authors and editors for Onco-this-week declare no financial benefits or remuneration from the sponsors. The sponsorships support the non-profit organization, PhD Career Support Group. The research conducted by authors and editors is a voluntary effort to popularize science for the public on behalf of PhD CSG.
This blog is strictly for news and information. It does not provide medical advice, diagnosis or treatment. This content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or another qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.
